share_log

Allarity Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Streeterville Capital LLC(14.7%),Streeterville Management LLC(14.7%), etc.

Allarity Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Streeterville Capital LLC(14.7%),Streeterville Management LLC(14.7%), etc.

Allarity Therapeutics | SC 13G:超过5%持股股东披露文件-Streeterville Capital LLC(14.7%),Streeterville Management LLC(14.7%)等
美股SEC公告 ·  2024/08/29 16:01

Moomoo AI 已提取核心信息

Streeterville Capital LLC, along with Streeterville Management LLC and John M. Fife, have filed a Schedule 13G with the SEC, indicating a significant ownership stake in Allarity Therapeutics Inc. The filing, dated August 19, 2024, reports that Streeterville Capital LLC directly owns 8,999,800 shares of Allarity Therapeutics' common stock, representing 14.7% of the company's class of securities. John M. Fife, a U.S. citizen, is identified as the person with the authority to receive notices and communications regarding this ownership. The shares provide Streeterville Capital LLC with sole voting power and sole dispositive power over 2,114,737 shares. The filing asserts that the securities were acquired in the ordinary course of business and not with the purpose of changing or influencing the control of the issuer.
Streeterville Capital LLC, along with Streeterville Management LLC and John M. Fife, have filed a Schedule 13G with the SEC, indicating a significant ownership stake in Allarity Therapeutics Inc. The filing, dated August 19, 2024, reports that Streeterville Capital LLC directly owns 8,999,800 shares of Allarity Therapeutics' common stock, representing 14.7% of the company's class of securities. John M. Fife, a U.S. citizen, is identified as the person with the authority to receive notices and communications regarding this ownership. The shares provide Streeterville Capital LLC with sole voting power and sole dispositive power over 2,114,737 shares. The filing asserts that the securities were acquired in the ordinary course of business and not with the purpose of changing or influencing the control of the issuer.
Streeterville Capital LLC与Streeterville Management LLC以及John M. Fife向美国证券交易委员会(SEC)提交了一份13G表,表明其在Allarity Therapeutics Inc.拥有重要的股权。提交日期为2024年8月19日,报告显示Streeterville Capital LLC直接持有Allarity Therapeutics的普通股8,999,800股,占公司证券类别的14.7%。美国公民John M. Fife被认定为接收关于此所有权的通知和通信的人。这些股份使Streeterville Capital LLC对2,114,737股拥有唯一的投票权和唯一的处分权。提交文件声称这些证券是在正常的业务活动中获得的,而不是为了改变或影响发行者的控制权。
Streeterville Capital LLC与Streeterville Management LLC以及John M. Fife向美国证券交易委员会(SEC)提交了一份13G表,表明其在Allarity Therapeutics Inc.拥有重要的股权。提交日期为2024年8月19日,报告显示Streeterville Capital LLC直接持有Allarity Therapeutics的普通股8,999,800股,占公司证券类别的14.7%。美国公民John M. Fife被认定为接收关于此所有权的通知和通信的人。这些股份使Streeterville Capital LLC对2,114,737股拥有唯一的投票权和唯一的处分权。提交文件声称这些证券是在正常的业务活动中获得的,而不是为了改变或影响发行者的控制权。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息